Search

Your search keyword '"Audoin, B."' showing total 11 results
Start Over Author "Audoin, B." Journal neurology
11 results on '"Audoin, B."'

1. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis

Author

Laplaud, David-Axel, Casey, Romain, Barbin, Laetitia, Debouverie, Marc, De Sèze, Jérôme, Brassat, David, Wiertlewski, Sandrine, Brochet, Bruno, Pelletier, Jean, Vermersch, Patrick, Edan, Gilles, Lebrun-Frenay, Christine, Clavelou, Pierre, Thouvenot, Eric, Camdessanché, Jean-Philippe, Tourbah, Ayman, Stankoff, Bruno, Al Khedr, Abdullatif, Cabre, Philippe, Lubetzki, Catherine, Papeix, Caroline, Berger, Eric, Heinzlef, Olivier, Debroucker, Thomas, Moreau, Thibault, Gout, Olivier, Bourre, Bertrand, Wahab, Abir, Labauge, Pierre, Magy, Laurent, Defer, Gilles, Guennoc, Anne-Marie, Maubeuge, Nicolas, Labeyrie, Céline, Patry, Ivania, Nifle, Chantal, Casez, Olivier, Michel, Laure, Rollot, Fabien, Leray, Emmanuelle, Vukusic, Sandra, Foucher, Yohann, Fontaine, B., Marignier, R., Durand-Dubief, F., Mathey, G., Le Page, E., Peaureaux-Averseng, D., Ouallet, J.C., Ruet, A., Collongues, N., Hautecoeur, P., Zephir, H., Maillard, E., Cohen, M., Derache, N., Branger, P., Ayrignac, X., Carra-Dalliere, C., Fromont, A., Chamard-Witkowski, L., Taithe, F., Moisset, X., Audoin, B., Rico-Lamy, A., Castelnovo, G., Giannesini, C., Fagniez, O., Bensa, C., Gueguen, A., Kasonde, I. Tabellah, De Vilmarest, A., Montcuquet, A., Vaillants, M., Beltran, S., Creange, A., Ayache, S., Abdellaoui, M., Pottier, C., Slesari, I., Deburghraeve, V., Neau, J.P., Servan, J., Pico, F., Henry, C., and Hankiewicz, K.

Published
2019
Full Text
View/download PDF

2. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults

Author

Cobo-Calvo, A., Ruiz, A., Maillart, E., Audoin, B., Zephir, H., Bourre, B., Ciron, J., Collongues, N., Brassat, D., Cotton, F., Papeix, C., Durand-Dubief, F., Laplaud, D., Deschamps, R., Cohen, M., Biotti, D., Ayrignac, X., Tilikete, C., Thouvenot, E., Brochet, B., Dulau, C., Moreau, T., Tourbah, A., Lebranchu, P., Michel, L., Lebrun-Frenay, C., Montcuquet, A., Mathey, G., Debouverie, M., Pelletier, J., Derache, N., Coustans, M., Rollot, F., De Seze, J., Vukusic, S., Marignier, R., Casey, D. R., Maze, D. M., Olaiz, D. J., Frangoulis, D. B., Debard, N., Vukusic, P. S., Zorila, D. C., Debouverie, P. M., Guillemin, P. F., Mathey, D. G., Ziegler, A., Edan, P. G., Le Page, D. E., Leray, D. E., Muraz, R., Brassat, P. D., Clanet, P. M., Peaureaux-Averseng, D. D., Dewas, C., Brochet, P. B., Ouallet, D. J., Ruet, D. A., Kounkou, K. K., De Seze, P. J., Collongues, D. N., Berthe, C., Vermersch, P. P., Hautecoeur, P. P., Deruelle, F., Papeix, D. C., Maillard, D. E., Lubetzki, P. C., Lebrun-Frenay, D. C., Cohen, D. M., Callier, C., Derache, D. N., Droulon, K., Labauge, P. P., Ayrignac, D. X., Carra-Dalliere, D. C., Pinna, F., Moreau, P. T., Fromont, D. A., Protin, A., Michel, D. L., Wiertlewski, D. S., Jousset, N., Berger, D. E., Chamard-Witkowski, D. L., Bereau, D. M., Cappe, C., Clavelou, P. P., Taithe, D. F., Moisset, D. X., Dumont, E., Pelletier, P. J., Audoin, P. B., Rico-Lamy, D. A., Di Lelio, B., Castelnovo, D. G., Stankoff, P. B., Giannesini, D. C., Heinzlef, D. O., Fagniez, D. O., Laage, D. C., Bourre, D. B., Lefaucheur, D. R., Maltete, D. D., Vimont, C., Al Khedr, D. A., Sehaki, S., Gout, D. O., Bensa, D. C., Cabre, P. P., Kasonde, D. I., Galli, P., Magy, P. L., Montcuquet, D. A., Nicol, M., Casez, D. O., Vaillant, D. M., Diop Kane, M., Camdessanche, P. J., Visneux, V., Guennnoc, D. A., Beltran, D. S., Meunier, G., Creange, P. A., Ayache, D. S., Abdellaoui, D. M., Pottier, D. C., Slesari, D. I., Sampaio, M., Deburghraeve?, D. V., Le Port, D., Ciron, D. J., Neau, P. J., Rabois, E., Labeyrie, D. C., Patry, D. I., Lescieux, E., Nifle, D. C., Servan, D. J., Pico, P. F., Chatagner, V., Camus-Jacqmin, D. M., Henry, D. C., Bottin, D. L., Castex, C., Diallo, S. S., Brisset, J. C., Cervenansky, F., Commovick, O., Defer, P. G., Durand-Dubief, D. F., Guttmann, P. C., Tourbah, P. A., Lifticariu, D. C., Constans, D. J., Tanguy, D. J., Dousset, P. V., Tourdias, D. T., Dardel, D. P., Oesterle, D. H., Gonin, D. S., Ricolfi, D. F., Grand, D. S., Krainik, D. A., Boncoeur-Martel, D. M., Ameli, D. R., Bonhomme, D. G., Cotton, P. F., Roch, D. J., Sappey-Marinier, D. D., Brunel, H., Coze, S., Girard, Nicolas, Lehmann, P., Ranjeva, P. J., Menjot De Champfleur, Nicolas, Anxionnat, P. R., Desal, D. H., Mondot, D. L., Savatovsky, D. J., Galanaud, P. D., Pyatigorskaya, D. N., Guillevin, D. R., Pierot, D. L., Barillot, D. C., Ferre, D. J., Bannier, E., Gerardin, D. E., Boutet, D. C., Kremer, D. S., Armspach, P. J., Berry, P. I., Bonneville, P. F., Dufay, N., Zephir, D. H., Gele, P., Marignier, D. R., Fiard, G., Lehmann, S., Lommazi, S., Laplaud, P. D., Gallot, G., Thouvenot, P. E., Fontaine, P. B., Rebeix, I., Desille-Dugast, M., CHU Pitié-Salpêtrière [APHP], Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), Neurologie, maladies neuro-musculaires [Hôpital de la Timone - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Hôpital de Hautepierre [Strasbourg], Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], RMN et optique : De la mesure au biomarqueur, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Département de Neuroradiologie [Centre Hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Département de Neurologie [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-IFR70-CHU Pitié-Salpêtrière [APHP], Department of Neurology, CHU Lyon, Centre Hospitalier Universitaire de Nice (CHU Nice), Département de neurologie [Montpellier], Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [Montpellier]-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes), Institut de Génomique Fonctionnelle (IGF), Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Centre National de la Recherche Scientifique (CNRS), Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U1215, Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Universitaire de Reims (CHU Reims), Observatoire astronomique de Strasbourg (ObAS), Université de Strasbourg (UNISTRA)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS), Université Nice Sophia Antipolis - Faculté de Médecine (UNS UFR Médecine), Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de Neurologie [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Hospices Civils de Lyon (HCL), CIC Strasbourg (Centre d’Investigation Clinique Plurithématique (CIC - P) ), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nouvel Hôpital Civil de Strasbourg-Hôpital de Hautepierre [Strasbourg], Centre de recherche en neurosciences de Lyon (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre hospitalier universitaire de Nantes (CHU Nantes), The Functional Electrical Neuroimaging Laboratory, Université de Lausanne (UNIL), Department of Economics, École Polytechnique, Palaiseau Cedex, 91128, France, affiliation inconnue, Alimentation et sciences sociales (ALISS), Institut National de la Recherche Agronomique (INRA), CHU Marseille, Infections Virales et Pathologie Comparée - UMR 754 (IVPC), Institut National de la Recherche Agronomique (INRA)-École pratique des hautes études (EPHE)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, ISL, Laboratoire Charles Coulomb (L2C), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Instituto de Tecnologia Ceramica, Universitat Jaume I, CHU Grenoble, Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), Service de Neurologie [Rennes] = Neurology [Rennes], CHU Pontchaillou [Rennes], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Strasbourg (UNISTRA)-Hôpital de Hautepierre [Strasbourg]-Nouvel Hôpital Civil de Strasbourg, Institut National de la Recherche Agronomique (INRA)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Claude Bernard Lyon 1 (UCBL), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Université Nice Sophia Antipolis (1965 - 2019) (UNS), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département de Neurologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-IFR70-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université, Hôpital Gui de Chauliac [Montpellier]-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS), COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [CHU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université de Montpellier (UM), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Lausanne = University of Lausanne (UNIL), Institut National de la Recherche Agronomique (INRA)-École Pratique des Hautes Études (EPHE), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), and Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
0301 basic medicine, medicine.medical_specialty, Visual acuity, [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, business.industry, Hazard ratio, Encephalopathy, Myelitis, Retrospective cohort study, Lower risk, medicine.disease, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Internal medicine, medicine, Optic neuritis, Neurology (clinical), medicine.symptom, 10. No inequality, business, ComputingMilieux_MISCELLANEOUS, 030217 neurology & neurosurgery, Survival analysis
Abstract

ObjectiveTo describe clinical and radiologic features associated with myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) in a large French nationwide adult cohort, to assess baseline prognostic features of MOG-Ab-associated diseases after a first acute demyelinating syndrome, and to evaluate the clinical value of MOG-Ab longitudinal analysis.MethodsClinical data were obtained from 197 MOG-Ab-positive patients ≥18 years of age. Complete imaging data were available in 108, and 54 serum samples were eligible for longitudinal evaluation. For survival analysis comparison, 169 aquaporin-4 antibody (AQP4-Ab)-positive patients from the NOMADMUS database were included.ResultsMedian age at onset was 36.46 (range 18.0–76.8) years, and patients were predominantly white (92.9%) with male:female ratio, 1.1. Clinical phenotype at onset included optic neuritis or myelitis in 90.86%, isolated brainstem or encephalopathy syndromes in 6.6%, and a combination of syndromes in 2.5%. Distinctive brain MRI findings in MOG-Ab-positive patients were thalamic and pontine lesions. Cortical and leptomeningeal lesions were found in 16.3% and 6.1%, respectively. The probability of reaching a first relapse after 2 and 5 years was 44.8% and 61.8%, respectively. MOG-Ab-positive patients were at lower risk at presentation of further clinical relapse (hazard ratio [HR] 0.45, 95% confidence interval [CI] 0.26–0.79) compared to AQP4-Ab-positive individuals. MOG-Ab-positive individuals had a lower risk of reaching Disability Status Scale score of 3.0 (HR 0.46, 95% CI 0.22–0.94) and visual acuity of 20/100 (HR 0.23, 95% CI 0.07–0.72). Finally, MOG-Ab titers were higher at relapse than in remission (p = 0.009).ConclusionIn adults, MOG-Ab-associated disease extends beyond clinical and radiologic abnormalities in the optic nerve and spinal cord. Despite the relapsing course, the overall visual and motor outcome is better compared with AQP4-Ab-positive patients.

Published
2018

3. Long-term follow-up of neuromyelitis optica with a pediatric onset

Author

Collongues, N., primary, Marignier, R., additional, Zéphir, H., additional, Papeix, C., additional, Fontaine, B., additional, Blanc, F., additional, Rodriguez, D., additional, Fleury, M., additional, Vukusic, S., additional, Pelletier, J., additional, Audoin, B., additional, Thouvenot, E., additional, Camu, W., additional, Barroso, B., additional, Ruet, A., additional, Brochet, B., additional, Vermersch, P., additional, Confavreux, C., additional, and de Seze, J., additional

Published
2010
Full Text
View/download PDF

4. Neuromyelitis optica in France: A multicenter study of 125 patients

Author

Collongues, N., primary, Marignier, R., additional, Zephir, H., additional, Papeix, C., additional, Blanc, F., additional, Ritleng, C., additional, Tchikviladze, M., additional, Outteryck, O., additional, Vukusic, S., additional, Fleury, M., additional, Fontaine, B., additional, Brassat, D., additional, Clanet, M., additional, Milh, M., additional, Pelletier, J., additional, Audoin, B., additional, Ruet, A., additional, Lebrun-Frenay, C., additional, Thouvenot, E., additional, Camu, W., additional, Debouverie, M., additional, Creange, A., additional, Moreau, T., additional, Labauge, P., additional, Castelnovo, G., additional, Edan, G., additional, Le Page, E., additional, Defer, G., additional, Barroso, B., additional, Heinzlef, O., additional, Gout, O., additional, Rodriguez, D., additional, Wiertlewski, S., additional, Laplaud, D., additional, Borgel, F., additional, Tourniaire, P., additional, Grimaud, J., additional, Brochet, B., additional, Vermersch, P., additional, Confavreux, C., additional, and de Seze, J., additional

Published
2010
Full Text
View/download PDF

5. Early Maintenance Treatment Initiation and Relapse Risk Mitigation After a First Event of MOGAD in Adults: The MOGADOR2 Study.

Author

Deschamps R, Guillaume J, Ciron J, Audoin B, Ruet A, Maillart E, Pique J, Benyahya L, Laplaud DA, Michel L, Collongues N, Cohen M, Ayrignac X, Thouvenot E, Zephir H, Bourre B, Froment Tilikete C, Moreau T, Cantagrel P, Kerschen P, Cabasson S, Maubeuge N, Hankiewicz K, Nifle C, Berger E, Megherbi H, Magy L, Klapczynski F, Sarov Riviere M, Giannesini C, Hamelin L, Giroux M, Branger P, Maurousset A, Mathey G, Moulin M, Mélé N, Papeix C, and Marignier R

Subjects
Humans, Male, Female, Adult, Middle Aged, Aged, Young Adult, Autoantibodies blood, France epidemiology, Cohort Studies, Follow-Up Studies, Optic Neuritis, Recurrence, Myelin-Oligodendrocyte Glycoprotein immunology
Abstract

Background and Objectives: Because myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently identified autoimmune disorder, the natural history of MOGAD is still not well described. The objective of this study was to describe the long-term outcomes of adult patients with MOGAD. In addition, we aimed to identify factors affecting relapse risk and neurologic outcomes., Methods: Clinical and biological data were obtained from patients with a first event of MOGAD and included in the French nationwide incident cohort between February 2014 and March 2017. Only patients aged 18 years or older at disease onset and with observation period of at least 3 months were included. Data were collected prospectively until July 2023 and registered in the dedicated French nationwide database. This form includes every relapse with phenotype description during follow-up, date of last assessment, final clinical outcome with Expanded Disability Status Scale score and visual acuity, and maintenance therapy. The probability of recurrence-free survival was assessed using the Kaplan-Meier method., Results: We included 128 patients. The onset phenotype was isolated optic neuritis in 81 patients (63.3%) and isolated myelitis in 25 patients (19.5%). The median follow-up duration was 77.8 months (range 3.2-111.2), with 49 patients (38.3%) experienced at least one relapse. Median times from onset to second and third attacks were 3.2 (1.0-86.2) and 13.0 (2.6-64.4) months, respectively. At the last assessment, Expanded Disability Status Scale Score was ≥3 and ≥6 in 22 (17.2%) and 6 (4.7%) patients, respectively. Eighty patients received at least one maintenance treatment. This treatment was initiated after the first attack in 47 patients (36.7% of the whole cohort) and at the time of a second attack in 25 (19.5%). Multivariate analysis revealed that initiating maintenance treatment after the first attack was associated with a lower relapse risk (OR = 0.26 [95% CI 0.11-0.62], p = 0.002). In patients receiving maintenance therapy after first attack, the 2-year, 4-year, 6-year, and 8-year relapse risks were 11%, 15%, 20%, and 20%, respectively. In other patients, the risks were 41%, 46%, 51%, and 56%., Discussion: The highest risk of a relapse in MOGAD occurs early, and initiating maintenance therapy from the first attack substantially reduced the relapse risk., Classification of Evidence: This study provides Class III evidence that initiating maintenance therapy from the first attack in patients with MOGAD reduces the relapse risk.

Published
2024
Full Text
View/download PDF

7. Rituximab De-escalation in Patients With Neuromyelitis Optica Spectrum Disorder.

Author

Demuth S, Collongues N, Audoin B, Ayrignac X, Bourre B, Ciron J, Cohen M, Deschamps R, Durand-Dubief F, Maillart E, Papeix C, Ruet A, Zephir H, Marignier R, and De Seze J

Subjects
Humans, Rituximab, Autoantibodies, Disability Evaluation, Recurrence, Neuromyelitis Optica therapy
Abstract

Background and Objectives: Exit strategies such as de-escalations have not been evaluated for rituximab in patients with neuromyelitis optica spectrum disorder (NMOSD). We hypothesized that they are associated with disease reactivations and aimed to estimate this risk., Methods: We describe a case series of real-world de-escalations from the French NMOSD registry (NOMADMUS). All patients met the 2015 International Panel for NMO Diagnosis (IPND) diagnostic criteria for NMOSD. A computerized screening of the registry extracted patients with rituximab de-escalations and at least 12 months of subsequent follow-up. We searched for 7 de-escalation regimens: scheduled discontinuations or switches to an oral treatment after single infusion cycles, scheduled discontinuations or switches to an oral treatment after periodic infusions, de-escalations before pregnancies, de-escalations after tolerance issues, and increased infusion intervals. Rituximab discontinuations motivated by inefficacy or for unknown purposes were excluded. The primary outcome was the absolute risk of NMOSD reactivation (one or more relapses) at 12 months. AQP4+ and AQP4- serotypes were analyzed separately., Results: We identified 137 rituximab de-escalations between 2006 and 2019 that corresponded to a predefined group: 13 discontinuations after a single infusion cycle, 6 switches to an oral treatment after a single infusion cycle, 9 discontinuations after periodic infusions, 5 switches to an oral treatment after periodic infusions, 4 de-escalations before pregnancies, 9 de-escalations after tolerance issues, and 91 increased infusion intervals. No group remained relapse-free over the whole de-escalation follow-up (mean: 3.2 years; range: 0.79-9.5), except pregnancies in AQP+ patients. In all groups combined and within 12 months, reactivations occurred after 11/119 de-escalations in patients with AQP4+ NMOSD (9.2%, 95% CI [4.7-15.9]), from 0.69 to 10.0 months, and in 5/18 de-escalations in patients with AQP4- NMOSD (27.8%, 95% CI [9.7-53.5]), from 1.1 to 9.9 months., Discussion: There is a risk of NMOSD reactivation whatever the rituximab de-escalation regimen., Trial Registration Information: Registered on ClinicalTrials.gov: NCT02850705., Classification of Evidence: This study provides Class IV evidence that de-escalation of rituximab increases the probability of disease reactivation., (© 2023 American Academy of Neurology.)

Published
2023
Full Text
View/download PDF

9. Evaluation of efficacy and tolerability of first-line therapies in NMOSD.

Author

Poupart J, Giovannelli J, Deschamps R, Audoin B, Ciron J, Maillart E, Papeix C, Collongues N, Bourre B, Cohen M, Wiertlewski S, Outteryck O, Laplaud D, Vukusic S, Marignier R, and Zephir H

Subjects
Adult, Antibodies therapeutic use, Aquaporin 4 drug effects, Aquaporin 4 immunology, Azathioprine adverse effects, Female, Humans, Male, Middle Aged, Mycophenolic Acid administration & dosage, Neuromyelitis Optica immunology, Recurrence, Rituximab therapeutic use, Azathioprine therapeutic use, Immunosuppressive Agents therapeutic use, Mycophenolic Acid therapeutic use, Neuromyelitis Optica drug therapy
Abstract

Objective: To compare the efficacy and the risk of severe infectious events of immunosuppressive agents used early as first-line therapy in patients with neuromyelitis optica spectrum disorder (NMOSD)., Methods: We retrospectively included patients with NMOSD and a seropositive status for aquaporin 4 or myelin oligodendrocyte glycoprotein antibodies beginning first-line immunosuppressants within 3 years after the disease onset. The main outcome was occurrence of relapse after the initiation of immunosuppressants; the secondary outcome was the annual relapse rate (AAR)., Results: A total of 136 patients were included: 62 (45.6%) were treated with rituximab (RTX), 42 (30.9%) with mycophenolate mofetil (MMF), and 23 (16.9%) with azathioprine (AZA). Compared with RTX-treated patients, the risk of relapse was higher among MMF-treated patients (hazard ratio [HR], 2.74 [1.17-6.40]; p = 0.020) after adjusting for age at disease onset, sex, antibody status, disease duration, ARR before treatment, corticosteroid intake, and relapse location. We did not observe any difference between RTX-treated and AZA-treated patients (HR, 2.13 [0.72-6.28]; p = 0.17). No interaction was found between the antibody status and immunosuppressive treatments. ARR was lower with RTX than with MMF ( p = 0.039), but no difference was observed with AZA. We observed 9 serious infectious events with MMF, 6 with RTX, and none with AZA., Conclusions: The use of first-line RTX in NMOSD appears more effective than MMF in suppressing clinical activity, independent of the antibody status., Classification of Evidence: That study provides Class III evidence that for patients with NMOSD, first-line RTX is superior to MMF to reduce the risk of relapse., (© 2020 American Academy of Neurology.)

Published
2020
Full Text
View/download PDF

10. Brain MRI features and scoring of leukodystrophy in adult-onset Krabbe disease.

Author

Cousyn L, Law-Ye B, Pyatigorskaya N, Debs R, Froissart R, Piraud M, Federico A, Salvatore S, Cerase A, Macário MC, Durães J, Kim SH, Adachi H, Audoin B, Ayrignac X, Da Y, Henderson R, La Piana R, Laule C, Nakamagoe K, Raininko R, Schols L, Sirrs SM, Viader F, Jastrzębski K, Leclercq D, and Nadjar Y

Subjects
Adolescent, Adult, Age of Onset, Aged, Child, Corpus Callosum pathology, Demyelinating Diseases pathology, Female, Humans, Internal Capsule pathology, Leukodystrophy, Globoid Cell diagnostic imaging, Magnetic Resonance Imaging methods, Male, Middle Aged, Pyramidal Tracts pathology, White Matter pathology, Young Adult, Brain diagnostic imaging, Leukodystrophy, Globoid Cell pathology
Abstract

Objective: To perform a systematic analysis and scoring of brain MRI white matter hyperintensities (WMH) in adult-onset Krabbe disease., Methods: We retrospectively collected basic clinical data and the first available brain MRI from patients with confirmed Krabbe disease with first clinical manifestations beyond 10 years of age. Data were obtained from our reference center for lysosomal diseases (n = 6) and from contacted authors of published articles describing patients with adult-onset Krabbe disease (n = 15). T2-weighted fluid-attenuated inversion recovery images of each patient were analyzed and scored using a radiologic score of WMH in a single center., Results: The corticospinal tract was always affected by WMH (100% of patients), however, with some distinctions along the tract: the precentral gyrus (100%), corona radiata (95%), and posterior internal capsule (81%) were highly abnormal, whereas the mesencephalon (57%), pons (52%), and medulla oblongata (5%) were less affected. WMH were also frequently present in the posterior lateral periventricular white matter (95%), optic radiations (86%), postcentral gyrus (71%), medial lemniscus (62%), and corpus callosum, especially in the isthmus (71%), whereas the genu was always normal. A few patients did not have the classical MRI pattern but extensive hyperintensities (n = 3), or patchy distribution of hyperintensities mimicking an acquired etiology (n = 2), or very subtle hyperintensities of the corticospinal tract (n = 1)., Conclusions: We specified the main locations of WMH, which were observed in the earliest stages of the disease and were also present in patients with atypical MRI pattern, highlighting the importance of radiologic features to guide the diagnosis., (© 2019 American Academy of Neurology.)

Published
2019
Full Text
View/download PDF

11. Increased total sodium concentration in gray matter better explains cognition than atrophy in MS.

Author

Maarouf A, Audoin B, Pariollaud F, Gherib S, Rico A, Soulier E, Confort-Gouny S, Guye M, Schad L, Pelletier J, Ranjeva JP, and Zaaraoui W

Subjects
Adult, Atrophy etiology, Atrophy pathology, Case-Control Studies, Disability Evaluation, Disease Progression, Female, Gray Matter diagnostic imaging, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Multiple Sclerosis, Relapsing-Remitting diagnostic imaging, Neuropsychological Tests, Statistics, Nonparametric, Tritium metabolism, Cognition Disorders etiology, Gray Matter metabolism, Multiple Sclerosis, Relapsing-Remitting complications, Sodium metabolism
Abstract

Objective: To investigate whether brain total sodium accumulation assessed by 23 Na MRI is associated with cognitive deficit in relapsing-remitting multiple sclerosis (RRMS)., Methods: Eighty-nine participants were enrolled in the study (58 patients with RRMS with a disease duration ≤10 years and 31 matched healthy controls). Patients were classified as cognitively impaired if they failed at least 2 tasks on the Brief Repeatable Battery. MRI was performed at 3T using 23 Na MRI to obtain total sodium concentration (TSC) in the different brain compartments (lesions, normal-appearing white matter [NAWM], gray matter [GM]) and 1 H- magnetization-prepared rapid gradient echo to assess GM atrophy (GM fraction)., Results: The mean disease duration was 3.1 years and the median Expanded Disability Status Scale score was 1 (range 0-4.5). Thirty-seven patients were classified as cognitively preserved and 21 as cognitively impaired. TSC was increased in GM and NAWM in cognitively impaired patients compared to cognitively preserved patients and healthy controls. Voxel-wise analysis demonstrated that sodium accumulation was mainly located in the neocortex in cognitively impaired patients. Regression analysis evidenced than the 2 best independent predictors of cognitive impairment were GM TSC and age. Receiver operating characteristic analyses demonstrated that sensitivity and specificity of the GM TSC to classify patients according to their cognitive status were 76% and 71%, respectively., Conclusions: This study provides 2 main findings. (1) In RRMS, total sodium accumulation in the GM is better associated with cognitive impairment than GM atrophy; and (2) total sodium accumulation in patients with cognitive impairment is mainly located in the neocortex., (© 2016 American Academy of Neurology.)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results